EN | |

RESEARCH & DEVELOPMENT

Our Development Pipeline – Innovative Drugs

Uni-GLP(injection pen)2022 expected

Pre-clinicalCTAPhase IPhase IIPhase IIIRegistrationMarketed

Uni-GLP(for obesity)TBC

Pre-clinicalCTAPhase IPhase IIPhase IIIRegistrationMarketed

Uni-GLP(new formulation)TBC

Pre-clinicalCTAPhase IPhase IIPhase IIIRegistrationMarketed

Uni-PTH(powder)Coming soon

Pre-clinicalCTAPhase IPhase IIPhase IIIRegistrationMarketed

Uni-PTH(injection pen)2022 expected

Pre-clinicalCTAPhase IPhase IIPhase IIIRegistrationMarketed

Uni-PTH(new formulation)TBC

Pre-clinicalCTAPhase IPhase IIPhase IIIRegistrationMarketed

Our Development Pipeline – Generic Drugs

PINUPCompleted soon

ResearchApplicationBE testANDACompleted

ArcarboseCompleted soon

ResearchApplicationBE testANDACompleted

Mitiglinide2021 expected

ResearchApplicationBE testANDACompleted

Uni-Bio Science is committed to creating novel high-value, patented drugs via its in-house R&D capabilities.

Uni-Bio Science's growing pipeline of drug candidates is focused on addressing unmet medical needs in the areas of diabetes, ophthalmology, and dermatology.

The Company's Research & Development team of highly-trained specialists focuses on the development of complex, next-generation biologics and small-molecule drugs. The team has a strong track record in clinical development and regulatory expertise.

Uni-Bio Science is one of the leading regional biotech players with a track record in successfully developing new drugs through its clinical pipeline.